Tag Archives: mdco

Medicines Company Spikes On Report Of Possible Sale

Shares of biotech The Medicines Co. (MDCO) jumped Wednesday on a report that the company is exploring a sale. Bloomberg cited anonymous sources in its report early Wednesday, which did not name a potential buyer. Medicines Co.’s financials have been suffering lately due to the loss of patent exclusivity on lead drug Angiomax, but the stock has stayed relatively buoyant due to hopes for cholesterol drug candidate ALN-PCSsc, which it is developing

Medicines Co., Alnylam Jump Ahead In Cholesterol Race

Biotechs The Medicines Co. (MDCO) and Alnylam Pharmaceuticals (ALNY) both got multiple price target increases Monday after they announced positive data on their anti-cholesterol drug candidate over the weekend. At the annual congress of the European Society of Cardiology, Medicines Co. and Alnylam presented results of their phase-one trial of ALN-PCSsc, which divided subjects with high LDL cholesterol (LDL-C) into various different dosage groups,

Medicines Co., Eagle Pharma Up On Analyst Actions

Drugmakers The Medicines Company (MDCO) and Eagle Pharmaceuticals (EGRX) were both rising on bullish analyst actions Monday in the wake of Thursday’s court ruling overturning the patents on Medicines’ cardiovascular drug Angiomax, or bivalirudin. The appeals-court decision would seem to be bad news for Medicines, but Mizuho Securities analyst Mario Corso upgraded the stock to buy from neutral Monday on the grounds that fears about the decision had